Avalo Therapeutics, Inc. AVTX
8.51 USD +1.35 (+18.85%)
At closeNov 11, 2026, 5:52 PM EST
8.40 -0.11 -1.29%
After hours · Nov 11, 5:52 PM ET
7.17 Day range 8.55
6.53 52-week range 24.27
- YTD
- -53.14%
- 1 year
- -45.10%
News
zacks.com Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks Avalo Therapeutics (AVTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts…
benzinga.com Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $20 Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $22 to $20.
benzinga.com Avalo Therapeutics Q3 EPS $(0.34) Beats $(0.61) Estimate Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.61) by 44.26 percent. This is a 84.47 percent increase over losses of…
globenewswire.com Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 Advancing AVTX-010, a next-generation, long-acting…
globenewswire.com Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for…
seekingalpha.com Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3 Avalo Therapeutics' positive LOTUS results now support a pivotal trial, and its monthly dosing gives it a potential differentiating factor in HS. Their balance sheet has enough runway to meet their…
benzinga.com This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Analysts downgraded DECK, AVTX, ORI, GL and CASS; price targets were cut for DECK, ORI and GL.
benzinga.com Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $22 Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $34 to $22.- benzinga.com BTIG Maintains Buy on Avalo Therapeutics, Lowers Price Target to $10 BTIG analyst Julian Harrison maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $58 to $10.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market…
benzinga.com Nasdaq Down 400 Points; Tesla Shares Fall After Q3 Results US stocks fell, led by Nasdaq’s 1.54% drop. Tesla slid 2% despite an earnings beat; oil rose, while gold and Asian markets declined.
defenseworld.net Avalo Therapeutics (NASDAQ:AVTX) Hits New 52-Week Low – Time to Sell? Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) hit a new 52-week low on Wednesday. The stock traded as low as $11.99 and last traded at $12.01, with a volume of 1,648,996 shares. The stock…
globenewswire.com Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for…
benzinga.com Avalo Therapeutics To Present Abdakibart Data At EADV Congress 2026 Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today…
globenewswire.com Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for…
defenseworld.net Christopher Ryan Sullivan Sells 12,394 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) CFO Christopher Sullivan sold 12,394 shares of Avalo Therapeutics stock in a transaction dated Wednesday, September 16th. The shares were…
globenewswire.com Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for…
seekingalpha.com Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise Avalo Therapeutics (AVTX) is now a well-funded, registrational-stage biotech with validated Phase II data for abdakibart in hidradenitis suppurativa (HS). Abdakibart demonstrated statistically…
globenewswire.com Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for…- benzinga.com Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48 Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.
- benzinga.com HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $35 to $30.
benzinga.com Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.58) by 43.1 percent. This is a 56.77 percent increase over losses of…
globenewswire.com Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for…
globenewswire.com Avalo Therapeutics to Participate in the BTIG Biotechnology Conference WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway…
globenewswire.com Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum WAYNE, Pa. , July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway…
benzinga.com Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38 Leerink Partners analyst Thomas Smith initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $38.- benzinga.com Avalo Therapeutics To Be Added To Small-Cap Russell 2000 Index And Broad-Market Russell 3000 Index, Effective June 26 Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today…
globenewswire.com Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway…
globenewswire.com Avalo Therapeutics Appoints Ron Philip to Board of Directors WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Avalo Therapeutics Advances AVTX-010, Long-Acting Next-Gen Anti-IL-1β mAB With Potential For Development In HS And Additional Inflammatory Disorders; IND Submission Planned For H1 2027 Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the…
globenewswire.com Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated…
benzinga.com This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's analyst ratings page. See analyst views on ICUI, BDSX,.
benzinga.com This FormFactor Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday Wall Street analysts upgraded EDU, MKTX, and FORM stocks. Check out their ratings on Benzinga's analyst ratings page before buying EDU.
benzinga.com This Sailpoint Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday Wall Street analysts downgrade ADBE and SAIL, cutting price targets. Check other analysts' views on these stocks. Photo via Shutterstock.
benzinga.com This Keurig Dr Pepper Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on top names. See analyst rating changes for PepsiCo, Octave Intelligence, Fervo Energy, Avalo Therapeutics, and Keurig Dr Pepper.
benzinga.com B of A Securities Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $35 B of A Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $35.
globenewswire.com Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated…- benzinga.com Citizens Maintains Market Outperform on Avalo Therapeutics, Lowers Price Target to $55 Citizens analyst Jason N. Butler maintains Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperform and lowers the price target from $62 to $55.
benzinga.com These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results Avalo Therapeutics reported better-than-expected Q1 loss due to positive trial results. Analysts maintain Buy ratings with lowered price targets.- benzinga.com Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $34 Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $40 to $34.
benzinga.com Apple To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday Analyst ratings for top names changed: Doximity cut to neutral, National Vision lowered price target, Starbucks upgraded to buy, Commercial Metals raised to buy, Wix.Com target lowered, MDxHealth…- benzinga.com Mizuho Maintains Outperform on Avalo Therapeutics, Raises Price Target to $45 Mizuho analyst Joseph Catanzaro maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and raises the price target from $39 to $45.
- benzinga.com HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $35 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $40 to $35.
- benzinga.com Avalo Therapeutics Q1 EPS $(0.98) Beats $(1.13) Estimate Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.13) by 13.27 percent. This is a 21.6 percent increase over losses of…
- benzinga.com Piper Sandler Maintains Overweight on Avalo Therapeutics, Raises Price Target to $60 Piper Sandler analyst Yasmeen Rahimi maintains Avalo Therapeutics (NASDAQ:AVTX) with a Overweight and raises the price target from $48 to $60.
benzinga.com Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results Avalo Therapeutics Inc (NASDAQ:AVTX) shares are surging after the company delivered a major clinical win, strengthened its balance sheet with a new offering and picked up fresh support from Wall…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Davita, Bloomin' Brands, Compass And Other Big Stocks Moving Higher On Wednesday Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised guidance. Other gaining stocks include EVC, BLMN, MNKD, FLEX, HUT, AVTX, COMP, VCYT, and SSRM.